Jetema Co

Jetema Co EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Jetema Co (216080.KQ) as of Oct 24, 2026 is 1.83 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was 1.54 % — a change of 18.53% (higher).

EBIT/Assets

1.83 %

YoY

18.53%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Jetema Co is 2025 1.83 % . Operating Income to Assets Ratio (EBIT/Assets) of Jetema Co was 2024 1.54 % . It decreases by 18.53% higher compared to the previous year.

The Jetema Co EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2017
-21.11 KRW
Jan 1, 2018
-8.87 KRW
Jan 1, 2019
-17.25 KRW
Jan 1, 2020
-12.69 KRW
Jan 1, 2021
1.54 KRW
Jan 1, 2025
1.83 KRW
The Jetema Co EBIT/Assets history
YEAREBIT/AssetsYoY
1.83 %+18.53%
1.54 %-112.14%
-12.69 %-26.40%
-17.25 %+94.38%
-8.87 %-57.97%
-21.11 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Jetema Co Stock analysis

What does Jetema Co do? Jetema Co., Ltd. generates revenue through the manufacturing and distribution of aesthetic products such as dermal fillers, threads, botulinum toxin, and other medical devices. The company develops and sells hyaluronic acid fillers for facial beauty, medical devices for wrinkle, contour, and volume improvement, and laser equipment for treating leukoplakia, psoriasis, and alopecia areata. Additional products include the lifting medical device epiticons, cosmetic mask packs, and pharmaceutical excaine creams. The primary buyers are medical professionals and clinics seeking cosmetic and dermatological solutions. The company's product portfolio targets the aesthetic and medical device market segments, focusing on non-surgical beauty treatments and skin condition therapies. Jetema Co., Ltd. serves customers in the healthcare sector who require advanced medical devices for cosmetic procedures and dermatological care. The business model centers on direct sales of these specialized medical products to healthcare providers and clinics. Jetema Co., Ltd. operates with a workforce of 187 full-time employees based in Wonju, Gangwon-Do, and has been engaged in the development and manufacturing of hyaluronic acid fillers since its inception. The company's offerings are designed to address specific medical and cosmetic needs, with a focus on facial beauty and skin treatments. Revenue is derived from the sale of these medical devices and related products to healthcare professionals and clinics. Jetema Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jetema Co stock

Operating Income to Assets Ratio (EBIT/Assets) of Jetema Co is 1.83 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Jetema Co changed from 1.54 % to 1.83 %, representing a 18.53% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Jetema Co since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Jetema Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Jetema Co

All Key Metrics — Jetema Co